The medicine cabotegravir, injected every eight weeks, is “highly effective” against HIV, like PrEP (pre-exposure prophylaxis), according to a study published this week by the global HIV Prevention Trials Network (HPTN).
Volunteers who received cabotegravir at the aforementioned frequency showed “much lower” HIV infection rates than volunteers who, in parallel, used the drug Truvada as PrEP.
Fifty people acquired HIV during the study – 38 were treated with Truvada and the rest with cabotegravir injections.
The research was carried out with 4.570 HIV-negative people in the countries of South Africa, Argentina, Brazil, the United States of America, Peru, Thailand and Vietnam, under the coordination of Beatriz Grinsztejn, head of the STD and AIDS clinical research laboratory at the Evandro Chagas National Institute of Infectious Diseases, and Raphael Landovitz, associate professor at the University of California at Los Angeles.
The information is from Folhapress (via Zero hour).
